MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
10.90
-1.18 (-9.73%)
May 6, 2025, 4:00 PM EDT - Market closed
MBX Biosciences Employees
MBX Biosciences had 43 employees as of December 31, 2024. The number of employees increased by 16 or 59.26% compared to the previous year.
Employees
43
Change (1Y)
16
Growth (1Y)
59.26%
Revenue / Employee
n/a
Profits / Employee
-$1,440,047
Market Cap
364.16M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 43 | 16 | 59.26% |
| Dec 31, 2023 | 27 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
MBX News
- 14 days ago - MBX Biosciences to Participate in Citizens and RBC May Investor Conferences - GlobeNewsWire
- 5 weeks ago - MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 7 weeks ago - MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 2 months ago - MBX Biosciences Announces Additions to Leadership Team - GlobeNewsWire
- 2 months ago - MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism - GlobeNewsWire
- 2 months ago - MBX Biosciences to Participate in March Investor Conferences - GlobeNewsWire
- 4 months ago - MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia - GlobeNewsWire
- 6 months ago - MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia - GlobeNewsWire